Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer

References

• Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The Developing Countries Vaccine Manufacturers’ Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008; 26:1611-5; PMID:18294742; http://dx.doi.org/10.1016/j.vaccine.2008.01.034
   PubMed Web of Science ®Google Scholar
• Beurret M, Hamidi A, Kreeftenberg H. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries. Vaccine 2012; 30:4897-906; PMID:22683521; http://dx.doi.org/10.1016/j.vaccine.2012.05.058
   PubMedGoogle Scholar
• Sharma HJ, Multani AS, Dutta AK, Joshi SM, Malik S, Bhardwaj S, Chakravarty A, Namjoshi GS, Parekh S, Verma V. Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials. Hum Vaccin 2009; 5:483-7; PMID:19395868
   PubMed Web of Science ®Google Scholar
• Li H, Li MG, Tang J, Liang L, Li YN, He L, Ye Q. Development of a quantitative ELISA method for total antibody of Haemophilus influenzae type b. Chinese Journal of Biologicals 2011; 24:974-6.
   Google Scholar
• Kreeftenberg JG, Hamidi A. Annex 5: Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. World Health Organization (WHO); 2004. Report No.: WHO/IVB/04.21. Available from: 627 http://whqlibdoc.who.int/hq/2004/WHOIVB04.21(302KB).pdf
   Google Scholar
• Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, et al. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children. Hum Vaccin 2011; 7:451-7; PMID:21403463; http://dx.doi.org/10.4161/hv.7.4.14208
   PubMed Web of Science ®Google Scholar
• Sharma HJ, Patil VD, Lalwani SK, Manglani MV, Ravichandran L, Kapre SV, Jadhav SS, Parekh SS, Ashtagi G, Malshe N, et al. Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process. Vaccine 2012; 30:510-6; PMID:22119927; http://dx.doi.org/10.1016/j.vaccine.2011.11.067
   PubMedGoogle Scholar
• Sharma H, Yadav S, Lalwani S, Gupta V, Kapre S, Jadhav S, Chakravarty A, Parekh S, Palkar S. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants. Vaccine 2011; 29:2359-64; PMID:21288803; http://dx.doi.org/10.1016/j.vaccine.2011.01.054
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Biological Standardization. WHO TRS No. 978- Sixty-first Report, 2010. Annex 6: Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies.
   Google Scholar
• WHO report on Increasing access to vaccines through technology transfer and local production, 2011: http://www.who.int/phi/publications/Increasing_Access_to_Vaccines_Through_Technology_Transfer.pdf
   Google Scholar
• WHO report on Trends in Local Production of Medicines and Related Technology Transfer, 2011: http://apps.who.int/medicinedocs/documents/s19063en/s19063en.pdf
   Google Scholar
• World Health Organization. Annex1: WHO guidelines on nonclinical evaluation of vaccines. WHO TRS No. 927; 2005.
   Google Scholar
• Fernández-Santana V, Cardoso F, Rodriguez A, Carmenate T, Peña L, Valdés Y, Hardy E, Mawas F, Heynngnezz L, Rodríguez MC, et al. Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b. Infect Immun 2004; 72:7115-23; PMID:15557635; http://dx.doi.org/10.1128/IAI.72.12.7115-7123.2004
   PubMed Web of Science ®Google Scholar
• Mawas F, Newman G, Burns S, Corbel MJ. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model. J Infect Dis 2005; 191:58-64; PMID:15593004; http://dx.doi.org/10.1086/426396
   PubMed Web of Science ®Google Scholar
• Fusco PC, Michon F, Laude-Sharp M, Minetti CA, Huang CH, Heron I, Blake MS. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 1998; 16:1842-9; PMID:9795390; http://dx.doi.org/10.1016/S0264-410X(98)00174-1
   PubMedGoogle Scholar
• Gupta RK, Anderson R, Cecchini D, Rost B, Xu J, Gendreau K, Saroff DL, Marchant C, Siber GR. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 1999; 27:167-76; PMID:10600208; http://dx.doi.org/10.1006/biol.1999.0204
   PubMedGoogle Scholar
• Siber GR, Anderson R, Habafy M, Gupta RK. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 1995; 13:525-31; PMID:7483772; http://dx.doi.org/10.1016/0264-410X(94)00042-L
   PubMed Web of Science ®Google Scholar
• Fernandez S, Cisney ED, Ulrich RG. Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery. Clin Vaccine Immunol 2013; 20:1690-6; PMID:23986319; http://dx.doi.org/10.1128/CVI.00215-13
   PubMed Web of Science ®Google Scholar
• Bacardí D, Cosme K, Aldana L, Merino N, Suárez J, Mosqueda O, Urquiza D, Romero J, Madrigal R, Amaya R, et al. Preclinical safety testing of the Quimi-Hib® vaccine adjuvanted with aluminum phosphate during product development. Biotecnol Apl 2013; 30:118-24
   Google Scholar
• Caulfield MJ, Smith JG, Wang S, Capen RC, Blondeau C, Lentsch S, Arminjon F, Sabouraud A. Immunogenicity of a hexavalent combination vaccine in rhesus monkeys. Vaccine 2000; 19:902-7; PMID:11115714; http://dx.doi.org/10.1016/S0264-410X(00)00299-1
   PubMedGoogle Scholar
• Fusco PC, Michon F, Laude-Sharp M, Minetti CASA, Huang CH, Heron I, Blake MS. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 1998; 16:1842-9; PMID:9795390; http://dx.doi.org/10.1016/S0264-410X(98)00174-1
   PubMedGoogle Scholar
• Alliance GAVI. Indian manufacturer cuts price of childhood vaccine by 30 percent: http://www.gavialliance.org/library/news/press-releases/2013/pentavalent-vaccine-30-percent-price-drop/
   Google Scholar
• OECD series on principles of good laboratory practice and compliance monitoring. Ann Ist Super Sanita. 1997;33(1):1-172.
   PubMedGoogle Scholar
• Hamidi A, Beurret M, inventors;2009(Sept. 6). Process for producing a capsular polysaccharide for use in conjugate vaccines. De Staat der Nederlanden, vert. door de minister van VWS, The Hague, NL, assignee. US Pat 7,582,459 B2.
   Google Scholar
• Hamidi A, Beurret M, inventors;2010(Mar. 3). Process for producing a capsular polysaccharide for use in conjugate vaccines. De Staat der Nederlanden, vert. door de minister van VWS, The Hague, NL, assignee. Eur Pat Spec 1 664 319 B1.
   Google Scholar
• WHO Expert Committee on Biological Standardization. Forty-ninth report. Annex 1. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Technical Report Series 2000;897:27-60.
   Google Scholar
• WHO Expert Committee on Biological Standardization. Forty-first report. WHO TRS No. 814 1991 Annex 1. Requirements for Haemophilus type b conjugate vaccines.
   Google Scholar
• European Pharmacopoeia 5.0. Haemophilus type b conjugate vaccine. 01/2005: 1219.
   Google Scholar
• Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983; 40:245-56; PMID:6601061
   PubMed Web of Science ®Google Scholar